Designing inhalable amorphous solid dispersions to mitigate crystallization risks in atropisomer development. (PubMed, Int J Pharm) - Jun 20, 2026 - "The development of inhalation formulations for CHF-6523, a selective PI3Kδ inhibitor, presents significant hurdles due to atropisomerism and a strong tendency to form amorphous solids, complicating the access to a suitable crystalline form of the pharmaceutically active isomer...Preliminary aerosol characterization confirmed the superior respirable fraction of the spray-dried ASD (∼73%), compared to blend (∼66%) and freeze-dried formulations (∼37%). This work demonstrates how atropisomer-related conformational dynamics can hinder crystalline form identification while guiding the development of stable amorphous formulations for inhalation therapies."
Journal • PIK3CD
|
|
Alessia Bacchi; Anna Giulia Balducci; Daniel Pecorari; Francesco Castagnini; Irene Bassanetti; Luca Fornasari; Luciano Marchiò; Matteo Betti; Paola Disisto; Rocco Bussolati; Valentina Mileo
|